BioMarin Pharmaceutical Inc. (LON:0HNC)

Market Cap	7.72B
Revenue (ttm)	2.30B
Net Income (ttm)	387.16M
Shares Out	n/a
EPS (ttm)	1.99
PE Ratio	19.95
Forward PE	10.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	636
Average Volume	2,607
Open	51.19
Previous Close	51.81
Day's Range	51.00 - 52.84
52-Week Range	51.00 - 73.33
Beta	n/a
RSI	44.23
Earnings Date	Oct 24, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNC

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD